- Research works
- 90 ▲ 3418% vs 2013–17
- Citations
- 1k 11.2 per fractional work
- Top-10% rate
- 14.0% record average 16.5%
- Open access
- 78% world 28%
Not ranked overall: Takeda (Austria) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 5.8×. Every wedge is a field page.
- Biochemistry, Genetics and Molecular Biology 5.8×
- Immunology and Microbiology 5.5×
- Pharmacology, Toxicology and Pharmaceutics 4.7×
- Chemical Engineering 2.5×
- Medicine 2.5×
- Nursing 1.6×
- Chemistry 0.8×
- Mathematics 0.6×
- Engineering 0.3×
- Materials Science 0.2×
- Agricultural and Biological Sciences 0.2×
- Physics and Astronomy 0.2×
- Computer Science 0.1×
- Economics, Econometrics and Finance 0.1×
- Health Professions 0.1×
- Environmental Science 0.1×
Which keywords describe research at Takeda (Austria)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Thrombosis, Gene Therapy, Hemostasis, Inflammation, SARS-CoV-2, Glycosylation, Vaccine and Monoclonal Antibodies.
- Thrombin
- Viral Vectors
- Immune Response
- AAV
- Pathogenesis
- Biosensors
- Protein Aggregation
- Tissue Inhibitors of Metalloproteinases
- Hemophilia
- Recombinant Proteins
- Cell Signaling
- Extracellular Matrix
- Therapeutic Antibodies
- Mammalian Cells
- Monoclonal Antibody
- Angiogenesis
- Vaccine
- SARS-CoV-2
- Hemostasis
- Thrombosis
- Inflammation
- Gene Therapy
- Epidemiology
- Glycosylation
- Monoclonal Antibodies
- Biopharmaceuticals
- Immunogenicity
- Recombinant Protein
- Cancer Progression
- Inhibitors
- Prophylaxis
- Factor VIII
- Matrix Metalloproteinases
- ACE2 Receptor
- Stability
- Immune Thrombocytopenic Purpura
- Platelets
- Antithrombotic Therapy
- Viral Transmission
- Protease-Activated Receptors
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Inflammation5▲ 5.2×11 topics
- Thrombosis5▲ 35×6 topics
- Gene Therapy4▲ 50×3 topics
- Hemostasis4▲ 96×3 topics
- Epidemiology4▲ 2.3×11 topics
- SARS-CoV-24▲ 28×4 topics
- Glycosylation3▲ 65×3 topics
- Vaccine3▲ 18×4 topics
- Monoclonal Antibodies3▲ 79×3 topics
- Angiogenesis3▲ 21×4 topics
- Biopharmaceuticals3▲ 122×3 topics
- Monoclonal Antibody3▲ 116×2 topics
- Immunogenicity3▲ 137×2 topics
- Mammalian Cells3▲ 251×1 topic
- Recombinant Protein3▲ 251×1 topic
- Therapeutic Antibodies3▲ 84×2 topics
- Cancer Progression3▲ 31×2 topics
- Extracellular Matrix3▲ 32×2 topics
- Inhibitors3▲ 138×2 topics
- Cell Signaling2▲ 35×3 topics
- Prophylaxis2▲ 42×2 topics
- Recombinant Proteins2▲ 161×2 topics
- Factor VIII2▲ 349×1 topic
- Hemophilia2▲ 349×1 topic
- Matrix Metalloproteinases2▲ 36×1 topic
- Tissue Inhibitors of Metalloproteinases2▲ 331×1 topic
- ACE2 Receptor2▲ 19×2 topics
- Protein Aggregation2▲ 90×1 topic
- Stability2▲ 21×1 topic
- Biosensors2▲ 8.3×4 topics
- Immune Thrombocytopenic Purpura2▲ 164×1 topic
- Pathogenesis2▲ 8.4×4 topics
- Platelets2▲ 62×1 topic
- AAV2▲ 99×1 topic
- Antithrombotic Therapy2▲ 51×2 topics
- Immune Response2▲ 7.3×4 topics
- Viral Transmission2▲ 27×2 topics
- Viral Vectors2▲ 99×1 topic
- Protease-Activated Receptors2▲ 198×1 topic
- Thrombin2▲ 198×1 topic
Which research topics does Takeda (Austria) publish most on?
By volume in 2022–2025: Viral Infectious Diseases and Gene Expression in Insects, Hemophilia Treatment and Research, Protease and Inhibitor Mechanisms and Protein purification and stability.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Viral Infectious Diseases and Gene Expression in Insects Molecular Biology 3 works
- 2 Hemophilia Treatment and Research Hematology 2 works
- 3 Protease and Inhibitor Mechanisms Cancer Research 2 works
- 4 Protein purification and stability Molecular Biology 2 works
- 5 Platelet Disorders and Treatments Hematology 2 works
- 6 Virus-based gene therapy research Genetics 2 works
- 7 Blood Coagulation and Thrombosis Mechanisms Hematology 2 works
- 8 SARS-CoV-2 detection and testing Infectious Diseases 2 works
- 9 SARS-CoV-2 and COVID-19 Research Infectious Diseases 1 works
- 10 Viral gastroenteritis research and epidemiology Infectious Diseases 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Takeda (Austria)'s research output changed?
Output in 2018–2022 was 3418% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Vienna
- University of Vienna
- TU Wien
- Medical University of Vienna
- BOKU University
- Vienna University of Economics and Business
- Austrian Academy of Sciences
- University of Veterinary Medicine Vienna
- Austrian Institute of Technology
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.